The phrase "evade treatment" is correct and usable in written English.
It can be used in contexts where someone is avoiding or escaping medical or therapeutic care.
Example: "Many individuals with mental health issues may choose to evade treatment due to stigma or fear."
Alternatives: "avoid treatment" or "escape treatment."
Yet many of these skin cancers harbor no known resistance-associated genetic mutations, leaving researchers and clinicians wondering how they manage to evade treatment.
Our study identifies a resistance mechanism in which tumour cells evade treatment by adopting an alternative identity that does not rely on the original oncogenic driver for survival.
Molecular reciprocity between the Ras/MEK/ERK and PI3K/Akt/mTOR pathways provides cancer cells with the ability to evade treatment when targeting only one pathway with monotherapy.
These properties may permit the parasites to evade treatment with sterol biosynthesis inhibitors in some clinical situations and need to be taken into account in the design of future drugs.
Building on model-driven perspectives and methods developed over the past 10 years, CaST has assembled a multidisciplinary community of Columbia University investigators who together are developing a novel framework for understanding how malignant tumors evade treatment, induce disease progression, and develop drug resistance.
This five-year grant will support the creation of the Center for Cancer Systems Therapeutics (CaST), a collaborative research center that will investigate the general principles and functional mechanisms that enable malignant tumors to grow, evade treatment, induce disease progression, and develop drug resistance.
Tinagl1 inhibited both pathways in distinct ways, overcoming the compensation mechanisms that the cancer uses to evade treatments.
Cancer cells are highly adaptable and often find ways to evade treatments aimed at only one target.
And while that information is still extremely valuable, it leaves much of the story untold; cancer cells are notorious for their ability to change, evolve and evade treatments, particularly as they spread in the body.
BAX expression is downregulated in hypoxia (Erler et al, 2004) and suppression of the pro-apoptotic BAX/BAK pathways is required for tumour cells to survive in hypoxic conditions and evade treatment-induced apoptosis (Nelson et al, 2004).
To better understand how GBM evades treatment, an international team led by Antonio Iavarone and Raul Rabadan at the Columbia University Center for Topology of Cancer Evolution and Heterogeneity has been studying how the cellular composition of GBM tumors changes over the course of therapy.
